Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Pharma Loses €10.2bn, 38,000 Jobs To Counterfeits As “Massive” Track & Trace Obligations Approach

Executive Summary

As a new report reveals that 4.4% of legitimate sales of drugs are lost each year in the EU due to counterfeiting, drug companies are being warned not to underestimate how much work they will need to do to comply with new track and trace rules.

You may also be interested in...



Ireland Chooses "Blueprint" System To Link Into Future EU Product Verification Network

New Irish system will link into the European verification network that is being set up to detect incidents of falsified medicines entering the supply chain using a "unique identifier" on most packs of prescription drugs, starting from February 2019.

EU Pharma Has Three Years To Comply With New Safety Feature Rules

The new EU rules on the safety feature to be attached to almost all prescription medicines have finally been published, and once they kick in products will have to carry a 'unique identifier' in the form of a 2D bar code on the pack that will allow its authenticity to be verified1.

European CHMP Opinions and MAA Updates

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel